RE:Nice startcanon12345 wrote: 1. Word is slowly getting out about the potential this company has. The overall market for this product has expanded 2 or 3 fold since the introduction of the vms 3.0.
2. Dr Adams initial target market is hospitals in the U.S, Canada and Europe. He estimates that there is a need for 40,000 units in those markets for existing medical conditions. Fda (or similiar) approval has been received in all those countries and units are now being used/tested in several major hospitals in these initial markets. To date reviews are all positive.
3. The Chinese market is also now being initiated with a partner in place in China and units being tested in hospitals there. The market there could be even larger then the market in 2.
4. Looking at the markets in 2&3 we can only speculate about other large markets and there potential (ie: India, Brazil etc. etc.). Interest has been expressed by other countries.
5. Covid longhaulers have greatly increased the need for this product and as we all know the need is growing on a daily basis. The 3.0 cannot get out fast enough to help in this area.
6. The Vet market is now also being tested. Animals (Dogs, Horses etc.) all have the same heart issues as we do. Again this market is in its very early stages but the 3.0 seems especially well suited to this market given how quick of a procedure it is and that the 3.0 does not require patients to remain completely still.
7. As you can see Ventripoint is only just now gaining market traction but Dr. Adams has made great strides in getting the product to key markets that will lead to overall market acceptance and use.
8. Nice start......... enormous potential!
Thanks for this. Word is getting out quick. Look at those bids this morning!